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Abstract
Background: The pharmacotherapeutic treatment of patients with cancer is generally associated with multiple
side-effects. Drug interactions and duplicate prescriptions between anti-cancer drugs or interactions with
medication to treat comorbidity can reinforce or intensify side-effects.
The aim of the present study is to gain more insight into the prevalence of drug interactions and duplicate pre-
scriptions among patients being treated in the outpatient day care departments for oncology and hematological
illnesses. For the first time the prevalence of drug interactions with OTC-drugs in cancer patients will be studied.
Possible risk factors for the occurrence of these drug-related problems will also be studied.
Methods/Design: A multicenter cross-sectional observational study of the epidemiology of drug interactions and
duplicate prescriptions is performed among all oncology and hemato-oncology patients treated with systemic anti-
cancer drugs at the oncology and hematology outpatient day care department of the VU University medical center
and the Zaans Medical Center.
Discussion: In this article the prevalence of potential drug interactions in outpatient day-care patients treated with
anti-cancer agents is studied using a novel more extensive screening method. If this study shows a high
prevalence of drug interactions clinical pharmacists and oncologists must collaborate to develop a pharmaceutical
screening programme, including an automated electronic warning system, to support drug prescribing for
ambulatory cancer patient. This programme could minimize the occurrence of drug related problems such as drug
interactions and duplicate prescriptions, thereby increasing quality of life.
Trial registration: This study is registered, number NTR2238.
Background
The pharmacotherapeutic treatment of patients with
cancer is generally associated with multiple side-effects.
The cause of the side-effects is usually due to the toxi-
city of the drugs themselves. In addition, drug interac-
tions can intensify side-effects. In general, interactions
are the cause of approximately 20-30% of all drug side-
effects, of which 70% needs clinical attention and 1-2%
is even life-threatening [1]. Cancer patients are particu-
larly susceptible to drug interactions [2]. In addition to
chemotherapy, cancer patients often use co-medication
to treat cancer related pain and venous thrombosis or to
reduce the side-effects of the anti-cancer drugs. Interac-
tions with drugs used to treat comorbidities can also
occur.
Drug interactions in nature are subdivided into two
types; pharmacokinetic and pharmacodynamic interac-
tions. Pharmacokinetic interactions alter the absorption,
distribution, metabolism or excretion of a drugs. The
majority of pharmacokinetic interactions are the result
of inhibiting the liver enzymes Cytochrome P450 [3].
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mechanism [4-6]. Furthermore, in cancer patients the
illness itself may also influence the pharmacokinetics of
drugs. For example the absorption of drugs can change
as a result of malnutrition and mucositis [2]. Impaired
kidney and liver function can also result in an abnormal
metabolism and excretion of a drug [2]. A pharmacody-
namic interaction occurs when two or more drugs act
on the same target site of clinical effect. Pharmacody-
namic interactions can be additive, synergistic or antag-
onistic and may influence the effectiveness or side
effects of drugs [3].
There is very little data available about the occurrence
of interactions and duplicate descriptions in patients
being treated with anticancer drugs. In literature various
studies can be found that describe the occurrence of
interactions and duplicate prescriptions in general clini-
cal departments [7-9]. However, the results of these stu-
dies are not representative for cancer patients.
Riechelmann et al [2] studied the prevalence of drug
interactions and duplicate descriptions between anti-
cancer drugs and medication to treat comorbidities.
This study showed that 27% of cancer patients are
exposed to interactions between anti-cancer drugs and
other drugs. Not one study has been undertaken into
the effect of using “Over The Counter” medication
(OTC medication). The clinical relevance of interactions
between anti-cancer drugs and OTC drugs is not
entirely clear. It is presumed that these interactions are
seriously under-reported [3].
Risk factors for the occurrence of interactions among
the general population are described extensively in lit-
erature. Research among the general population shows
that lung patients, patients who use anti-coagulant
drugs, patients with cardiovascular disease who use,
amongst other things, diuretics, nitrates, ACE-inhibitors
and Ca antagonists, patients older than 50 and patients
suffering from diabetes and kidney disorders belong to
the group with risk factors for the occurrence of interac-
tions and duplicate prescriptions [10,11]. It is not cer-
tain whether these risks factors in cancer patients using
anti-cancer drugs are the same. Research by Riechel-
mann et al. into clinical oncology patients suggests that
the use of eight or more drugs and a hospital stay of
more than six days represented a risk factor [12]. In
ambulatory cancer patients Riechelmann et al found an
increased risk for certain types of cancer (mainly brain
tumours) and patients receiving drugs to treat comor-
bidities [2].
Due to the lack of data available to the prescribing
oncologist about medication to treat comorbidities of
cancer patients, some drug-related problems such as
interactions and duplicate prescriptions that can occur
during the use of anti-cancer drugs are not being
recognised. Furthermore, due to poor transfer of medi-
cation information between the community pharmacy,
the general practitioner and the hospital, these drug-
related problems may not always be identified.
T h ea i mo ft h ep r e s e n ts t u d yi st og a i nm o r ei n s i g h t
into the prevalence of interactions and duplicate
prescriptions among patients being treated in the outpa-
tient day care departments for oncology and hemato-
oncology using a novel more extensive screening
method. For the first time the prevalence of drug inter-
actions with OTC-drugs in cancer patients will be stu-
died. Possible risk factors for the occurrence of these
drug-related problems will also be studied.
Methods
Study design and setting
A multicenter cross-sectional study of the epidemiology
of drug interactions and duplicate prescriptions is per-
formed during a five month period starting in november
2009 among all oncology and hemato-oncology patients
treated with systemic anti-cancer drugs at the (hemato-)
oncology outpatient day care department of the VU
University Medical Center and the Zaans Medical Cen-
ter. The VU University medical center is a large tertiary
referral hospital in Amsterdam. The Zaans Medical Cen-
ter is a small community hospital situated in Zaandam
(Amsterdam area).
Patients
In a five month period all patients with solid and hema-
tologic malignancy currently using systemic anti-cancer
drugs are asked to participate in the study. Exclusion
criteria: the use of trial medication, a lack of command
of the Dutch language and younger than 18 years old.
All participating patients are asked to sign Informed
Consent. The study is approved by the Medical Ethics
Board of the VU University medical center and the
Zaans Medical center.
Patient interview
Patients are asked questions by means of a structured
interview (RVL) (available online as an additional file).
Questions concern co-morbidities and the use of OTC
drugs. To determine the type of co-medication, an over-
view of drugs prescribed is obtained from the community
pharmacy and the actual use is discussed with the
patient. Data on the use of anti-cancer agents, diagnosis,
aim of treatment (palliative/adjuvant), treatment start
date and cancer-related co-medication is collected by
means of a medical chart review and, if necessary, by
means of interview of the prescribing doctor. Data on
renal function (creatinine) and liver function tests [aspar-
tate aminotransferase (ASAT), alanine aminotransferase
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obtained from the laboratory database of the hospital.
We define a laboratory abnormality as an increase of
50% or greater above the upper limit in plasma levels
measured within the prior 4 weeks (upper normal limits:
ASAT≤35 U/L, ALAT≤40 U/L, g-GT≤44 U/L, creati-
nine≤99 μmol/L).
Determinations of potential drug interactions and
duplicate prescriptions
Drugs are subdivided into four groups; “anti-cancer
agents”, “supportive care agents”, “medications to treat
comorbidity” and “OTC-drugs”.W ed e f i n e“anti-cancer
agents” as medication to treat solid or hematological
malignancies, “supportive care agents” as medications to
treat cancer- and/or therapy- related symptoms, “medi-
cations to treat comorbidity” as a non cancer clinical
condition that required pharmacologic treatment and
“OTC-drugs” as (alternative) medications and food sup-
plements used on the patients own initiative without
prior consultation of a doctor. For each patient we add
up the number of medications by group. If a medication
contained two or more pharmacologically active agents
each drug is counted individually in the analysis (e.g.
sulfamethoxazol combined with trimethoprim). The
drug is counted only once when a patient was taking
the same medication on more than one regimen (e.g.
long- and short-acting morphine). We define a duplicate
prescription as the concurrent use of two drugs of the
same class to treat the same condition. A duplicate pre-
scription can be both desirable (e.g. long- and short-
acting morphine) and undesirable. In this study only
undesirable duplicate prescriptions were analysed.
Drugs are screened for potential drug interaction by
the Drug Interaction Facts Software (Facts and Compar-
isons, version 4.0) [13], which has been shown to have
an accuracy of over 95% in detecting drug interactions
[14]. The program classifies interactions by level of
severity and level of scientific evidence [13]. Classifica-
tion is described in Table 1. Because of lack of clinical
significance drug interactions of minor severity will not
be included in the analysis.
Additionally, all drugs are manually screened for combi-
nations of drugs with QT-interval prolongating and/or
Torsades de Pointes (TdP) inducing properties using the
Arizona CERT system [15] and PubMed (QT-interaction).
Because of the potentially severe consequences we classify
all drug combinations with risk for QT-prolongation as
major. The level of scientific evidence is determined by
screening the electronic database PubMed.
Furthermore, drugs that may cause increased risk of
falling (CNS-depressant agents) are identified by using
handbooks and PubMed. If a combinations of two CNS-
depressant agents is detected this is counted as one
drug interaction (CNS-interaction) in the analyses. We
classify all CNS-interactions as moderate. The level of
evidence is determined by screening the electronic data-
base PubMed.
Drugs are also manually screened for the combination
between NSAID’s and corticosteroids, anticoagulants,
aspirin or SSRI’s (GI-interaction). These combinations
are known to increase the gastrointestinal bleeding risks
[16,17]. Because of the potentially severe consequences
we classify all GI-interactions as major. The level of
scientific evidence is determined by screening the elec-
tronic database PubMed.
To identify drug interactions of OTC-drugs we screen
pharmacology handbooks and electronic databases
PubMed and Thomson Micromedex.
The medication screened for drug interactions are the
medications of the 4 groups mentioned above; “anti-
cancer agents”, “supportive care agents”, “medications to
treat comorbidity” and “OTC-drugs”. We only count the
drug interactions in the analysis when an “anti-cancer
drug” or a “supportive care agents” is involved. We
don’t include potential drug interactions between non-
cancer drugs (drug interactions between two medica-
tions to treat comorbidity or OTC-drugs) in the
analysis.
Statistical analysis
Only few studies of drug interactions in oncology are
published in the literature. A sample of 300 patients is
chosen as a feasible sample. Patients will be asked to
participate in this study until this number is obtained.
Descriptive statistics (means ± SD or median) and fre-
quency analysis is applied to describe the whole study
sample with regard to demographics, cancer type, treat-
ment objective, type of anticancer drugs, comorbidities,
number of medications per patient and laboratory
Table 1 Classification of drug interactions by Drug
Interaction Facts Software 13
Classification Description
Severity
1 Major: life-threatening or permanent damage
2 Moderate: deterioration of patient’s status, treatment is
required
3 Minor: bothersome or little effect
Documentation
1 Established: proven to occur in well-controlled studies
2 Probable: very likely, but not proven clinically
3 Suspected: may occur; some good data, but needs
more study
4 Possible: could occur, but data are very limited
5 Unlikely: doubtful; no good evidence of a clinical
effect
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(severity, level of scientific evidence, onset and
mechanism).
Univariate and multivariate logistic regression analysis
will be performed to identify potential risk factors for
the occurrence of drug interactions. The dependent
variable is the number of drug interactions per patient.
Expected covariates are age, number of drugs per
patient, multicenter (Zaans Medical Center, VU Univer-
sity Medical Center), treatment intent (palliative/cura-
tive), treatment type (e.g. chemotherapy, hormone
therapy, combination therapy), presence of comorbid-
ities, tumor type (hemato-oncology/oncology) and the
use of at least one OTC-drug. Gender is not included as
a covariate due to the fact that certain cancer types only
occur in men or women. For binary or nominal vari-
ables, the largest group is taken as the referent. Vari-
ables with univariate P-values <0.1 are included in the
multivariate analysis. In the multivariate analysis a
P-value of <0.05 is considered statistically significant.
T h ed a t aa r ea d j u s t e df o rp o s s i b l ec o n f o u n d e r sa n d
effect modifiers (age, sex, type of cancer). Data are col-
lected and analysed in SPSS version 15.0 (SPSS Inc.,
Chicago, IL 60606).
Power calculation
The occurrence of drug interactions is the primary end-
point. Literature show that drug interactions occur in
approximately 27% of ambulatory cancer patients [2].
With an accuracy of 5% and 95% confidence interval, a
total of 300 patients is needed.
Discussion
In this study the prevalence of potential drug interac-
tions in outpatient day-care patients treated with anti-
cancer agents will be investigated using a novel more
extensive screening method. Additionally, risk factors
for the occurrence of drug interaction will be studied.
This study will provide more insights into drug interac-
tions among cancer patients and can be used to improve
the pharmaceutical patient care by setting up a routine
screening method to identify drug interactions.
The Drug Interaction Facts Software, which is used in
this study, shows great sensitivity in identifying drug
interactions [14] but doesn’t recognise all QT-interac-
tions, interactions that cause gastroduodenal toxicity
and CNS-interactions. In this study we will conduct an
additional manual search and use other databases to
gain more insight in the occurrence of QT-interactions,
interactions that can cause gastrointestinal toxicity and
CNS-interactions. Numerous drugs, representing a wide
range of pharmacologic classes, have been associated
with QT interval prolongation [15]. Due to possibly ser-
ious and even fatal consequences of drug combinations
that cause prolongation of the QT interval has led to
contraindicating the use of many drug combinations.
Falling in elderly patients is a major public health con-
cern as well. Most falls are the result of a combination
of intrinsic and extrinsic risk factors [18]. Prescribed
CNS-depressant medication is an important contributor
to the risk of falling in elderly [19]. Several commonly
used drugs (e.g. psychotropic and cardiovascular drugs)
are indentified as a risk factor for falls [20-22]. Multiple
CNS-depressant drug use may even lead to increased
risk of falling [23]. NSAID’s are also used extensively in
oncology as an analgesic. However, their use is limited
by gastrointestinal toxicity. Additional pharmacological
risk factors for the development of NSAID ulcers
include concomitant use of corticosteroids, anticoagu-
lants, aspirin and serotonin reuptake inhibitors (SSRI’s)
[17,18]. The additional search in these databases is
expected to increased the number of detected drug
interactions in our study population and give a more
valid insight in the prevalence of drug interactions in
cancer patients.
In this study we only include a drug interaction in the
analysis if an anti-cancer or a supportive care agent is
involved. Drug interactions between non-cancer agents
is beyond the scope of this study. A strength of our
study is that we included the use of OTC drugs in our
analysis to gain more insight into the prevalence of
interactions between OTC-drugs and anti-cancer drugs.
It is expected that OTC-drugs are used extensively in
cancer patients and the prevalence of drug interactions
with OTC-drugs will be high.
Due to the retrospective design of the study the clini-
cal consequences cannot be studied. However, a pro-
spective design could influenced prescribing by
oncologist. If this study shows a high prevalence of drug
interactions clinical pharmacists and oncologists must
collaborate to set up a screening programme to reduce
the occurrence of drug related problems. This screening
can be implemented for ambulatory cancer patients
before using anti-cancer drugs, in order to improve
their quality of life and minimize the occurrence of drug
interactions.
Additional material
Additional file 1: structured interview. structured interview for
collecting data.
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